Next Article in Journal
dNTP Supply Gene Expression Patterns after P53 Loss
Next Article in Special Issue
Cancer Cachexia: Muscle Physiology and Exercise Training
Previous Article in Journal
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Previous Article in Special Issue
Relative Expression of Vitamin D Hydroxylases, CYP27B1 and CYP24A1, and of Cyclooxygenase-2 and Heterogeneity of Human Colorectal Cancer in Relation to Age, Gender, Tumor Location, and Malignancy: Results from Factor and Cluster Analysis
Article Menu

Export Article

Open AccessArticle
Cancers 2012, 4(4), 1180-1211;

Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome

Informatics and Bio-computing Platform, Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada
European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
Department of Biochemistry, NYU School of Medicine, New York, NY 10016, USA
Author to whom correspondence should be addressed.
Received: 8 October 2012 / Revised: 31 October 2012 / Accepted: 2 November 2012 / Published: 8 November 2012
(This article belongs to the Special Issue System Biology in Cancer Research)
Full-Text   |   PDF [1361 KB, uploaded 8 November 2012]   |  


Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics. View Full-Text
Keywords: pathway database; pathway visualization; network visualization; cancer annotation; EGFR signaling pathway database; pathway visualization; network visualization; cancer annotation; EGFR signaling

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Milacic, M.; Haw, R.; Rothfels, K.; Wu, G.; Croft, D.; Hermjakob, H.; D'Eustachio, P.; Stein, L. Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome. Cancers 2012, 4, 1180-1211.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top